"Designing Growth Strategies is in our DNA"
The global insulin pump market size was USD 3.62 billion in 2020. The global impact of COVID-19 has been unprecedented and staggering, with insulin pump witnessing a negative impact on adoption rate across all regions amid the pandemic. Based on our analysis, the global market exhibited a lower growth of 11.7% in 2020 as compared to the average year-on-year growth during 2017-2019. The market is projected to grow from USD 4.13 billion in 2021 to USD 11.86 billion in 2028 at a CAGR of 16.0% in the 2021-2028 period. The rise in CAGR is attributable to this market’s demand and growth, returning to pre-pandemic levels once the pandemic is over.
Insulin pumps are small, computerized devices designed and programmed to deliver pre-determined doses of insulin into a diabetic person. The market for these pumps has grown and developed in recent years to cater to the rising demand for portable insulin delivery devices among diabetics. The major factor propelling this market is the increasing prevalence of diabetes, especially Type 1 Diabetes, worldwide. Moreover, the development of such advanced pumps powered by smart technologies, such as artificial intelligence (AI) and machine learning (ML), by leading medical device manufacturers has also emerged as a vital growth determinant for this market.
Such delivery systems can significantly improve sugar monitoring, remove the need for constant adjustments, and prevent erratic fluctuations. Another example is the 2018 innovation launched by Medtronic called Sugar.IQ, which it co-developed with IBM. Sugar.IQ is a diabetes assistant mobile app that uses predictive analytics and machine learning to analyze data related to blood glucose levels, food logs, and hypoglycemia.
Heightened Need for Portable Diabetes Management Solutions amid COVID-19 May Favor the Market
The outbreak of the COVID-19 pandemic has triggered an unprecedented global health emergency. Healthcare facilities are overwhelmed with coronavirus patients and in countries such as the UK and the US, national health authorities have suspended all non-essential surgeries and procedures to devote their attention and resources to COVID patients. These announcements, however, have proven disastrous for diabetics as they need frequent access to insulin medications to control their blood sugar levels. According to organizations such as the International Diabetes Federation and the American Diabetes Association, diabetes patients and other such preexisting conditions are likely to experience more severe symptoms and complications of COVID on account of their weakened immune systems.
Thus, the close linkage between chronic diseases and the severity of COVID-19 symptoms has heightened the need for effective and efficient diabetes management solutions amid this crisis. Portable and/or wearable insulin delivery devices are being increasingly seen as a viable solution in this dire scenario and the opportunities thus created have been leveraged by leading players in this market. Tandem Diabetes, for instance, reported in November 2020 that it achieved record sales in the third quarter of 2020, driven by the surging adoption of its Control-IQ technology, the first algorithm cleared by the US Food and Drug Administration (FDA) to be used in automated insulin pumps. Similarly, Insulet also registered higher earnings and revenues owing to the increasing uptake of its pumps by Type 2 diabetics. The company is also planning on launching a novel interoperable pump system in early 2021.
Request a Free sample to learn more about this report.
Incorporation of Smart Technologies to Fuel Growth
Smart technologies such as AI have rapidly penetrated the healthcare IT landscape and are now making steady headway in diabetes management. Spearheading these trends are medical device companies that are actively developing and introducing AI-enabled pumps and other automated drug delivery solutions. For example, Medtronic’s 670G system has been programmed to suspend insulin delivery in cases of actual or anticipated hypoglycemia (low blood sugar). On the other hand, the system has also been calibrated to automatically adjust base insulin rates for hyperglycemia.
These innovations are accelerating the transition from traditional insulin injections to more efficient and convenient pumps, resulting in greater patient satisfaction. Enabled by these factors, the market is expected to rise significantly during the forecast period.
Increasing Prevalence of Diabetes Worldwide to Aid Lasting Market Growth
Diabetes is a metabolic disease wherein the body is unable to convert the sugar in carbohydrates and fats into energy due to the inability of the body to produce insulin (Type 1 Diabetes) or the ineffective use of insulin production by the body (Type 2 Diabetes). As a consequence, glucose levels in the blood rise, necessitating an artificial infusion of insulin into the body, either through frequent injections or through these pumps. Thus, one of the most prominent factors catalyzing the insulin pump market growth is the rising number of diabetic patients around the globe. According to the International Diabetes Federation (IDF), in 2019, roughly 463 million adults worldwide were suffering from diabetes. By 2045, the IDF estimates that this number will swell to 700 million. Further, IDF’s analysis shows that over 1.1 million children and adolescents are living with Type 1 diabetes, while the proportion of people with Type 2 diabetes is expanding in most countries. Therefore, these pumps are set to play an instrumental role in supporting the management of this chronic disease in the next two decades.
Distinct Advantages of Insulin Pumps over Conventional Therapies to Boost the Market
The increasing popularity of these pumps is primarily stoked by the tangible benefits of these devices compared to the conventional multiple daily injections (MDI) therapy. A person with Type 1 diabetes, for instance, requires a daily infusion of insulin to maintain blood sugar levels. In the case of MDI, such infusion will either require the patient to visit a health facility every day or a health professional to jab the patient at home. These pumps remove this inconvenience entirely because these devices are attached to the patient and are programmed to deliver the medication as per the doctor’s recommendation. Furthermore, since the cannula of the pump is inserted into the skin, the need for frequent injections is thus eschewed altogether. In addition, as insulin supply can be adjusted on these pumps according to individual needs, the probability of elevated blood glucose levels in the morning or the occurrence of hypoglycemic episodes is substantially reduced. The considerable advantages offered by this computerized device over the MDI-based therapy are pushing patients towards adopting these compact machines and fueling their market in the process.
Furthermore, the advent of closed-loop insulin delivery systems has opened a new avenue of growth for this market. In a closed-loop system, an insulin device and a continuous glucose monitor (CGM) are connected through a smartphone app, such as CamAPS® FX, which runs on Android devices. Acknowledging the vast potential of this technology, regulatory bodies are also providing the necessary support to medical device companies. In December 2019, for instance, the US Food and Drug Administration (FDA) cleared Control-IQ, a closed-loop insulin pump-CGM system developed and manufactured by Tandem Diabetes Care.
Prohibitive Costs to Impede Growth
Modern drug delivery devices, such as insulin pumps, have disrupted traditional healthcare dynamics and have heralded the dawn of a new era in the healthcare industry. However, these devices come with a hefty price tag, making them virtually unaffordable to the average income earner. In the US, for example, without insurance, the out-of-pocket cost for a new device is around $6,000, with an additional $3,000-$6,000 for batteries and sensors. With the number of uninsured people in the US growing every year, coupled with the rising prevalence of diabetes, these insulin drug delivery systems are not accessible to a significant chunk of the American public. The situation is adverse in developing countries. For example, in India, the cost of these pumps is anywhere between INR 1lakh and INR 4lakh. Moreover, they are not covered under any health insurance scheme. Non-upgraded health reimbursement policies in developing economies and high costs of insulin devices in developed nations will be the two key growth-limiting factors for this market.
Alternative devices such as insulin pens may hamper market growth as they are cost-effective. For example, Companion Medical’s InPen, the only FDA-cleared advanced insulin pen, consists of a reusable injector smartpen that is connected to a phone app. The pen stores the insulin settings for the user and is programmed to calculate and manage the Multiple Daily Injections (MDI). This pen helps diabetic patients to take the right dose at the right time and track the data in real-time. Further, the smart device also stores the patient’s injection history, which can be shared with healthcare providers.
Pumps Segment to Experience Dynamic Growth through 2028
Based on product, this market has been categorized into pumps and consumables. Here, the pumps segment is set to lead the insulin pump market share on account of the growing adoption of these pumps among diabetics, underpinned by the significant advantages they offer over conventional injection-based treatments.
The consumables segment is expected to display a modest growth trajectory during the forecast period as insulin consumables, besides pumps, are also being increasingly adopted for managing diabetes. For example, insulin pens allow quick infusion of insulin into the body in case of an emergency.
To know how our report can help streamline your business, Speak to Analyst
Type 1 Segment Comprehensively Dominated the Global Market in 2020
On the basis of disease indication, the market has been divided into Type 1 diabetes and Type 2 diabetes. Among these, the Type 2 diabetes segment dictated the market share in 2020 owing to the rising prevalence of Type 1 diabetes across the globe. For example, the IDF estimates that worldwide, more than 1.1 million children and adolescents are living with Type 1 diabetes. Since patients with Type 1 diabetes are unable to produce insulin, their need for such pumps and other consumables is the highest.
The Type 2 diabetes segment’s share is also expected to expand steadily throughout the forecast period due to the increasing incidence of Type 2 diabetes around the world.
Retain Pharmacy to Gain Substantial Traction
In terms of distribution channel, the market has been segmented into hospital pharmacies, retail pharmacies, and online stores. With the growing availability of diabetes management devices and solutions in retail pharmaceutical outlets, the retail pharmacies segment is well poised to gain larger ground in this market.
However, the hospital pharmacies segment is anticipated to lead the market during the forecast period as the majority of patients prefer purchasing critical medical devices from pharmacies based in or affiliated with hospitals/clinics. Moreover, the prescription for the required insulin dosage is also provided by doctors in hospitals (in most cases), which favors this segment.
The proliferation of online medical stores is expected to enlarge the online stores segment’s share in the forthcoming years.
North America Insulin Pump Market Size, 2020 (USD Billion)
To get more information on the regional analysis of this market, Request a Free sample
By geography, the market has been grouped into North America, Europe, Latin America, and the Middle East & Africa.
North America is foreseen to command the market share over the forecast period on account of the favorable reimbursement environment in the US for insulin pumps. For example, Medicare Parts A & B cover tubeless and tubed pumps, respectively, requiring the patient to pay only 20% of the cost of the pump. In addition, the presence of medical device companies, such as Tandem and Insulet, in the region will also help the growth of the market.
In Europe, the market will be primarily driven by the rising incidence of diabetes. According to the World Health Organization (WHO), approximately 60 million people are affected by diabetes across Europe, with high blood sugar killing roughly 3.4 million annually in the region. The WHO also estimates that diabetes-related deaths will double by 2050 in Europe. This is likely to surge the demand for these pumps and other such diabetes management devices in the region.
The global insulin pumps market in Asia Pacific is expected to rise at a substantial rate in the foreseeable years. The growth is attributed to the rising prevalence of chronic diseases such as diabetes, primarily due to the adoption of unhealthy lifestyles is contributing to the growth of this market. Another factor responsible for the growth is the increasing geriatric population. For instance, according to the World Bank, senior citizens accounted for 28.4% of the total population in Japan in 2018. The demand for advanced insulin delivery devices is increasing and this has encouraged researchers to invest more in R&D for manufacturing smart devices that can provide personalized results to the patients, thereby improving their quality of life. However, the high cost of these insulin pens is the only restraining factor in this region.
In Latin America and the Middle East & Africa, the steady rise in the incidence of diabetes is envisaged to spawn enormous opportunities for insulin pump manufacturers. For example, a study conducted by researchers from the National Institute of Minority Health and Health Disparities (USA), Ponce Health Sciences University (Puerto Rico), and Kaiser Permanente Health Research Center (USA) in October 2020 found that the prevalence of diabetes was high in Mexico, Haiti, and Puerto Rico, with nearly 50% of those affected being unaware of their condition. Similarly, in the Middle East & East Africa, the IDF estimates that diabetes will afflict around 108 million adults by 2045.
Monopolistic Competition to Govern Market Dynamics
The market is deeply consolidated, with medical device industry giants, such as Medtronic and Tandem, dominating the competitive landscape of this market. Strengthened by their financial prowess, these companies are making heavy investments in research & development activities to bring out innovative insulin delivery offerings in the market. The most notable strategies adopted by key players in this market include geographic expansion, product launches, portfolio diversification, collaborations with competitors and pharmaceutical companies, and attaining timely regulatory approvals.
An Infographic Representation of Insulin Pump Market
To get information on various segments, share your queries with us
The market research report provides qualitative and quantitative insights into the market at global as well as regional level along with the detailed analysis of market size and growth rate for all possible segments in the market.
Moreover, the industry analysis report provides an elaborative analysis of the global market dynamics and competitive landscape. Various key insights presented in the report are the price trend analysis, recent industry developments in the market, such as mergers & acquisitions, healthcare industry overview by key countries, and overview of latex allergy along with competitive landscape and company profiles.
Value (USD Billion)
By Product Type
By Disease Indication
By Distributional Channel
Fortune Business Insights says that the global market size stood at USD 3.62 billion in 2020 and is projected to reach USD 11.86 billion by 2028.
In 2020, the market value was USD 2.12 billion.
The market is expected to register a CAGR of 16.0% during the forecast period.
By disease indication, the Type 1 diabetes segment is set to lead the market in the foreseeable future.
The increasing prevalence of diabetes worldwide will be the key factor driving the growth of the market.
Medtronic, Tandem Diabetes Care, and Insulet Corporation are the major players in this market.
North America held the largest market share in 2020.
The incorporation of smart technologies in insulin delivery systems is the prominent trend in the market.
“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”- One of the Leading Food Companies in Germany
“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”- Intuitive Surgical
“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”- Major Food Company in Japan
“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”- Ziering Medical
“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”- Major Manufacturer of Precision Machine Parts in India
“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”- Hewlett-Packard
“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”- Global Management Consulting Firm
“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”- UK-based Start-up in the Medical Devices Sector
“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”- One of the Largest Companies in the Defence Industry